
Nutella launching new spread that will be made in suburban Chicago
Chicago, which has given rise to everything from the coffee maker and mobile phone to the Ferris wheel and now a new pope, is about to add another potentially groundbreaking development to its legacy: Nutella Peanut.
The first new version of Nutella's iconic hazelnut spread in its 60-year history is set to roll out next year from Italian candy giant Ferrero, with Chicago at the center of its plans.
Developed over five years by Ferrero's food scientists, Nutella Peanut will be made exclusively at its west suburban Franklin Park factory. Ferrero will invest $75 million in the plant and create 65 jobs to produce the hazelnut, peanut and chocolate mashup, the company said.
'We think it's going to be big,' said Seth Gonzalez, senior director of marketing for Nutella. 'We do plan on it becoming a significant part of the portfolio going forward, and so we hope that consumers will get behind it and come try it out.'
Nutella fans with a hankering for peanuts may have to wait a little bit, however.
The former Nestle plant, which Ferrero acquired in 2018, also makes peanut-packed Baby Ruth and Butterfinger candy bars, giving it a leg up to produce the new peanut-flavored spread, Gonzalez said. The plant is being retooled to add the first Nutella production line in the U.S. by January. Nutella Peanut is expected to hit store shelves in April 2026.
The made-in-Chicago creation — adding peanuts to a hazelnut spread with cocoa that has remained unchanged since its introduction in 1964 — will be marketed to the North American palate, where peanut butter is, of course, a staple.
But Nutella Peanut will retain the distinctively Euro flavor of the original spread.
'We didn't want it to be another peanut butter,' Gonzalez said. 'There's a reason why cocoa is still connected as a peanut-and-cocoa formula, instead of just peanuts. It's more afternoon snacking than lunch, for example.'
Ferrero will unveil Nutella Peanut, along with Ferrero Rocher chocolate squares and other innovations beginning Tuesday at the Sweets & Snacks Expo, an annual event born in Chicago, which is taking place this year in Indianapolis.
The new products represent the New World ambitions of the 80-year-old Ferrero, which in recent years has acquired several Chicago candy-makers, while introducing its European brands to the U.S.
'Developing Nutella and Ferrero Rocher products specifically for the North American market represents a defining moment in our company's history,' Michael Lindsey, president and chief business officer of Ferrero North America, said in a news release.
Founded in 1946 as a small pastry shop in Alba, Italy, privately held Ferrero is now the third-largest confectionery company in the world, with production plants across five continents and more than 47,500 employees.
Its legacy international products, including Nutella, Kinder and Ferrero Rocher, have been gaining traction in the U.S. in recent years, along with its growing portfolio of domestic brands.
Brought to the U.S. in the 1980s, Nutella's biggest market remains Europe.
'Nutella is the peanut butter of their market,' Gonzalez said.
Nutella revenue in the U.S. is up 8.8% year-over-year, and has grown by 88% since 2020, bolstered by the introduction of two new products — Nutella Biscuits and Nutella B-ready, the company said. Currently, Nutella products for the U.S. market are made at plants in Canada and Mexico.
But Chicago will become the nexus of North American manufacturing for Nutella Peanut.
'It's just a great hub of food and treats and snacks, manufacturing and marketing, and there's just a lot of great talent there and great technology infrastructure,' said Hugh McMullen, a Ferrero USA spokesperson. 'And it's been exciting to grow in Chicago and in the state of Illinois.'
Ferrero has built a significant footprint in Illinois, assembling a number of candy brands, investing in plants and growing to more than 1,700 employees at manufacturing, office and retail locations across the state.
In 2017, Ferrero bought century-old Chicago candy-makers Ferrara and Fannie May. The following year, it substantially broadened its U.S. portfolio and Illinois footprint with the $2.8 billion acquisition of Nestle's U.S. confectionery business, adding such brands as Butterfinger, Baby Ruth and Crunch, as well as factories in Bloomington, Franklin Park and Itasca.
Ferrero, whose U.S. headquarters are in Parsippany, N.J., has invested significantly in its Illinois properties, including $285 million in two expansions at its Bloomington plant, which makes everything from Crunch to Kinder Bueno, a European favorite introduced in the U.S. six years ago.
On the retail front, Ferrero opened its first Nutella Cafe eight years ago on Michigan Avenue in Chicago, serving such dishes as waffles and crepes topped with the hazelnut chocolate concoction. A Nutella Peanut menu item will be coming to the cafe next year, Gonzalez said.
In 2023, Ferrero launched its North American research and development facility at the Marshall Field building on State Street, where workers once minted Frangos on the 13th floor before the candies were outsourced to a Pennsylvania company at the dawn of the new millennium and the department store became Macy's. Chicago-based Garrett Brands, the owner of Garrett Popcorn Shops, bought the Frango chocolate brand from Macy's in 2018.
The Ferrero candy scientists have since created a number of innovations in the Chicago lab including new Butterfinger flavors — salted caramel and marshmallow — along with Crunch White and three new Keebler Chips Deluxe varieties.
While Nutella Peanut was developed at Ferrero's Alba, Italy, research center, the breakthrough may have a big impact in Chicago. If the Nutella Peanut launch is successful, the Franklin Park factory will likely be expanded to handle increased production and diversification to other Nutella products, Gonzalez said.
'We'll have to invest in a factory that already deals with peanuts, which means we're going to need more lines and expansion of our current facilities,' Gonzalez said. 'That's the goal.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
14 minutes ago
- Associated Press
INTRODUCING TANGLE, A REVOLUTIONARY PROTEIN PASTA, TO THE U.S.
Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Samyang Foods Relaunches Their Instant Pasta Brand in the U.S., with New Look and Flavors LOS ANGELES, June 4, 2025 /PRNewswire/ -- Samyang Foods – best known as the parent company of social media's most popular instant noodles, Buldak – is reintroducing a different kind of instant noodle to the U.S. – instant pasta! Initially launched in 2023, Tangle is making a triumphant return to American grocery stores this year, with a fresh new look and four delectable flavors. Tangle is a revolutionary one-pot pasta (all-in-one pasta bowl) that combines bold flavor with effortless convenience. Driven by a passion for creating delicious, hassle-free meals, it features bouncy noodles paired with distinctive, chef-inspired sauces. Each bowl is designed to offer a filling, high-quality meal that's hot and ready in 5 minutes. Beyond convenience, Tangle also packs nutritional value, offering 15 grams of protein and 4-7 grams of fiber per serving. Tangle is available in four crave-worthy varieties tailored to American tastes: Tangle Garlic Oil: A nod to the Italian classic aglio e olio, this pasta features roasted garlic, premium Spanish olive oil and a dash of crushed red pepper for a subtle kick. Tangle Creamy Mushroom: A luxuriously creamy pasta, infused with deep umami from a blend of truffle, white mushrooms and shiitake mushrooms. Tangle Chunky Tomato: A hearty, comforting dish with generous chunks of tomato, elevated by robust notes of garlic and onion. Tangle Bulgogi Alfredo: A unique East-meets-West fusion, combining the sweet and savory essence of Korean bulgogi with rich, creamy Alfredo-style sauce and hints of bok choy, carrots, and onions. More than a fast fix, Tangle offers a fresh take on everyday dining that is perfect for busy professionals, on-the-go students, or anyone looking for a flavorful upgrade to their routine. With modern flavors and a streamlined experience, Tangle invites consumers to rethink what pasta can be – delicious and effortless. 'Tangle represents our vision to blend quality and ease in a way that feels exciting and new,' said Youngsik Shin, CEO of Samyang America. 'It's not just about saving time – it's about bringing joy to every bite.' Tangle is currently available at Kroger and Asian grocery stores nationwide, as well as online via and will be launching at BJ's Wholesale Club starting in July. All four flavor varieties come in single-serve bowls for $2.99 each, or multi-packs for $8.49 per 4-piece bundle. Visit and follow on Instagram (@tangle_pasta) and TikTok (@tangle_us) to keep up with new releases. ABOUT SAMYANG FOODS Samyang Foods is the originator of South Korea's first-ever instant ramen, launched in 1963, delivering much-needed sustenance in a convenient and affordable package. Over six decades, Samyang Foods's innovative thinking and creativity have broadened the culinary landscape, providing nourishment and exciting new flavors to the world. Samyang Foods is the parent company of globally beloved food brands – Buldak, Tangle and Samyang. Whether offering comfort and joy, or igniting diverse and fresh inspiration, Samyang Foods is committed to enriching lives and paving the way for a prosperous future. Visit to learn more. MEDIA CONTACT: [email protected] View original content to download multimedia: SOURCE Samyang Foods USA
Yahoo
an hour ago
- Yahoo
Overactive Bladder Treatment Market to Reach USD 5.45 Billion by 2032, Driven by Aging Population, Drug Innovation, and Rising Awareness
According to Research by SNS Insider, U.S. Overactive Bladder Treatment Market Continues Steady Growth Amid High Prevalence of Urinary Disorders and Increased R&D Initiatives by Key Pharma Players. Austin, June 04, 2025 (GLOBE NEWSWIRE) -- Overactive Bladder Treatment Market Size & Growth Analysis: According to SNS Insider, the Overactive Bladder Treatment Market size was estimated at USD 3.63 billion in 2023 and is expected to reach USD 5.45 billion by 2032, at a CAGR of 4.64% during the forecast period of 2024-2032. The overactive bladder treatment market has been growing steadily owing to the increasing number of conditions associated with OAB and the availability of treatment modalities. It is due to rising aging populations, improved levels of diagnosis, and developing pharma treatments, which are some of the factors driving growth in the market. Furthermore, innovations in drugs are becoming safer and more potent, and the expanding access to healthcare facilities also remains a driving factor for the growth of the market a Sample Report of Overactive Bladder Treatment Market@ The U.S. overactive bladder treatment market was estimated at USD 1.05 billion in 2023 and is expected to reach USD 1.56 billion by 2032, at a CAGR of 4.53% during the forecast period of 2024-2032. The United States had the largest share in the North American overactive bladder treatment market owing to its high incidence of OAB conditions, well-developed healthcare infrastructure, and extensive presence of top pharma players. The nation is also favored by increased awareness and early detection, thus leading to higher treatment adoption. Overactive Bladder Treatment Market Report Scope Report Attributes Details Market Size in 2023 US$ 3.63 billion Market Size by 2032 US$ 5.45 billion CAGR CAGR of 4.64% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Segments By Disease Type (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder)By Type (Anticholinergics, Neuromodulation, Mirabegron, Botox, Other)By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) Segmentation Insights By Type, Mirabegron Segment Leads the Market Mirabegron dominated the overactive bladder treatment market in 2023 with a 26% market share, as it was more potent than conventional anticholinergic medications and had a better safety profile. Mirabegron (Myrbetriq), the first β3-adrenoceptor agonist on the market, is an alternative to antimuscarinics that has fewer serious side effects (e.g., xerostomia and constipation associated with antimuscarinics). Its once-daily dosing and improved patient compliance make it easier for patients to take while also benefiting doctors. By Disease Type, Idiopathic OAB Segment dominated the Overactive Bladder Treatment Market In 2023, the idiopathic overactive bladder segment accounted for the largest share in the market with 76% market share because it is highly prevalent and has a mysterious etiology, which demands treatment. Compared to neurogenic OAB, idiopathic conditions are without any recognizable neurological reason, thus prevailing more in the general population, particularly the elderly. The increasing population of elderly individuals, coupled with lifestyle and rising awareness rates, has accelerated diagnosis rates. Since drug treatments such as Mirabegron and antimuscarinics are widely prescribed for idiopathic patients, this category is still creating significant demand for the drugs as well as urological visits. By Distribution Channel, the Retail Pharmacies Segment Dominated the Overactive Bladder Treatment Market in 2023 The retail pharmacies segment led the market by 76% market share in 2023 because it was easily accessible, convenient, and could directly reach patients. The majority of overactive bladder drugs, such as Mirabegron and antimuscarinics, are prescribed and dispensed via retail pharmacies. Retail pharmacies offer direct counseling, assist in medication adherence, and typically serve as the first point of contact for chronic disease management. Need Any Customization Research on Overactive Bladder Treatment Market, Enquire Now@ Major Players Analysis Listed in this Report are: Astellas Pharma Inc. Pfizer Inc. AbbVie Inc. Teva Pharmaceutical Industries Ltd. Medtronic Plc. Viatris Inc. Hisamitsu Pharmaceutical Co. Inc. Johnson & Johnson Endo Pharmaceuticals Inc. Alembic Pharmaceuticals Limited Axonics Modulation Technologies Inc. Apotex Inc. Aurobindo Pharma Limited Cogentix Medical Inc. Intas Pharmaceuticals Ltd. Macleods Pharmaceuticals Ltd. Mylan N.V. Sanofi Sumitomo Pharma America Inc. (Urovant Sciences) Alembic Pharmaceuticals Limited. North America Leads the Overactive Bladder Treatment Market, Asia Pacific is the Most Rapidly Growing Region North America dominates the overactive bladder treatment market with a 37% market share in 2023 due to its established healthcare infrastructure, high patient awareness, and dominant access to advanced therapeutics. The region has the development of huge pharmaceutical companies along with an increasing population of elderly adults, who are more susceptible to urological conditions. Asia Pacific is expected to observe the fastest growth in the overactive bladder treatment market during the forecast period due to growing healthcare spending, rising awareness, and an expanding geriatric population. There are lots of investments in the field of healthcare around the regions of China, India, and Japan. Buy a Single-User PDF of Overactive Bladder Treatment Market Analysis & Outlook Report 2024-2032@ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)


Business Wire
an hour ago
- Business Wire
Rothschild & Co Hires Ralph Lerman as Managing Director in Business Services
NEW YORK--(BUSINESS WIRE)--Rothschild & Co announced that Ralph Lerman has joined the firm's North American Global Advisory business as a Managing Director on the Business Services team, effective immediately. Mr. Lerman will be based in New York. This expansion of the team underscores Rothschild & Co's commitment to growing its U.S. Business Services practice and delivering best-in-class advisory services to both sponsor-backed and corporate clients. 'Ralph is a respected banker with deep domain knowledge and client relationships,' said Jonathan Kaye, Global Co-Head of Business Services. 'Ralph was also a critical partner in building a world-class Services practice, and will be instrumental in building Rothschild & Co's franchise in key verticals in North America.' Mr. Lerman has nearly two decades of investment banking experience and a strong track record of advising on complex M&A transactions across the business services sector. He joins Rothschild & Co from Moelis & Company, where he served as Executive Director and originated and led transactions in professional services, human capital management, and a variety of tech enabled verticals. Mr. Lerman holds a B.A. from Tufts University and an M.B.A. with High Distinction from the University of Michigan's Ross School of Business. 'I've long admired Rothschild & Co's reputation for providing independent, high-impact advice across the globe and am excited to join the team at a time of real momentum in the business services sector,' said Ralph Lerman. 'I look forward to collaborating with my new colleagues to help clients navigate critical moments with the thoughtfulness and integrity for which the firm is known.' About Rothschild & Co, Global Advisory Rothschild & Co is a family-controlled and independent group and has been at the centre of the world's financial markets for over 200 years. With a team of c.4,600 talented financial services specialists on the ground in over 40 countries, Rothschild & Co's integrated global network of trusted professionals provide in-depth market intelligence and effective long-term solutions for our clients in Global Advisory, Wealth & Asset Management, and Five Arrows, its alternative assets arm. Global Advisory, a division of the Rothschild & Co group, designs and executes strategic M&A and financing solutions, providing impartial, expert advice to large and mid-sized corporations, private equity, families and entrepreneurs, and governments. Through its unrivalled network of 1,600 industry and financing specialists in 47 countries, Rothschild & Co's Global Advisory business combines the breadth of its advisory offering with a high volume of transactions to achieve a unique understanding and perspective into markets and participants worldwide.